Detalhe da pesquisa
1.
Loss of AMPKα2 promotes melanoma tumor growth and brain metastasis.
iScience
; 26(6): 106791, 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37213225
2.
Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.
bioRxiv
; 2023 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711814
3.
ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.
bioRxiv
; 2023 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873189
4.
Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas.
Cancer Metab
; 10(1): 6, 2022 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35193687
5.
Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
Mol Cancer Ther
; 8(3): 552-62, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19276167
6.
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
Cells
; 8(12)2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31766580
7.
Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.
Chem Biol
; 14(7): 813-23, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17656318
8.
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
Cell Metab
; 27(5): 977-987.e4, 2018 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29628419
9.
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
Cancer Cell
; 31(2): 225-239, 2017 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28196595
10.
ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.
Cancer Res
; 77(21): 5873-5885, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28887323
11.
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
Cancer Res
; 74(23): 7037-47, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25297634
12.
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.
Clin Cancer Res
; 20(21): 5537-46, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24803579
13.
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Clin Cancer Res
; 19(3): 657-67, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23251002
14.
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Pigment Cell Melanoma Res
; 25(2): 248-58, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22171948
15.
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Cancer Res
; 70(21): 8736-47, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20959481
16.
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Mol Cancer Ther
; 8(8): 2079-85, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19671763
17.
Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling?
Cell Cycle
; 5(23): 2738-43, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17172847